Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL7216847

N.OCCN1CCNCC1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.47
CXCR4 P61073 2/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SIGMAR1 Q99720 4/20 0.39
RAD52 P43351 1/20 0.39
KMT2A Q03164 4/20 0.38
MAPT P10636 1/20 0.38
CHRM5 P08912 2/20 0.38
CHRM3 P20309 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 2/20 0.37
ANPEP P15144 1/20 0.37
ERAP2 Q6P179 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361682 0.97
SCHEMBL1194 0.97
SCHEMBL8373240 0.97 POLB (0.50) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
SCHEMBL7683711 0.95 CXCR4 (0.52) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
SCHEMBL29505898 0.95 POLB (0.48) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
Hydrochloric Acid SCHEMBL7572884 0.95 SMN1; SMN2 (0.48) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
SCHEMBL29707540 0.95 POLB (0.48) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
SCHEMBL12958863 0.95 KDM4E (0.50) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
SCHEMBL13014195 0.95 CXCR4 (0.52) POLBSMN1; SMN2HSD17B10CXCR4KDM4E
Hydrochloric Acid SCHEMBL4078377 0.95 SMN1; SMN2 (0.48) POLBSMN1; SMN2HSD17B10CXCR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323043-B2 Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK PIERRE FABRE MEDICAMENT (FR) 2019-06-18 US disclosed
CN-105037689-B Intrinsic fire retarding epoxide resin of Halogen and preparation method thereof 四川大学 2018-01-30 CN disclosed
US-20170283432-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PIERRE FABRE MEDICAMENT (FR) 2017-10-05 US disclosed
CN-105037689-A Halogen-free intrinsic flame retardant epoxy resin and preparing method thereof UNIV SICHUAN 2015-11-11 CN disclosed
CN-102781571-B Catalyst and method for producing an amine BASF SE 2015-06-17 CN disclosed
CN-102639231-B Catalyst and method for producing an amine BASF SE 2014-12-10 CN disclosed
CN-103945935-A Process for producing Sn-containing catalysts BASF SE 2014-07-23 CN disclosed
CN-101903095-B Process for preparing amines BASF SE 2013-07-10 CN disclosed
CN-101903096-B Method for the production of an amine BASF SE 2013-04-03 CN disclosed
CN-101903094-B Process for producing amines BASF SE 2013-03-20 CN disclosed
CN-102781571-A Catalyst and method for producing an amine BASF SE 2012-11-14 CN disclosed
CN-102639231-A Catalyst and method for producing an amine BASF SE 2012-08-15 CN disclosed
CN-101903095-A Process for preparing amines BASF SE 2010-12-01 CN disclosed
CN-101903096-A Method for the production of an amine BASF SE 2010-12-01 CN disclosed
CN-101903093-A Method for producing an amine BASF SE 2010-12-01 CN disclosed
CN-101903092-A Method for producing an amine BASF SE 2010-12-01 CN disclosed
CN-101903094-A Process for producing amines BASF SE 2010-12-01 CN disclosed
CN-101903097-A Method for the production of an amine BASF SE 2010-12-01 CN disclosed
EP-1341412-A1 INDOLOCARBAZOLE ANTICANCER AGENTS AND METHODS OF USING THEM Advanced Life Sciences, Inc. (US) 2003-09-10 EP disclosed
WO-2002048166-A1 INDOLOCARBAZOLE ANTICANCER AGENTS AND METHODS OF USING THEM ADVANCED LIFE SCIENCES, INC. (US) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283432-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK JAK2, JAK3, JAK1 POLB 2802/4885SMN1; SMN2 4368/4885HSD17B10 3710/4885
US-10323043-B2 Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK JAK2, JAK3, JAK1 POLB 2802/4885SMN1; SMN2 4368/4885HSD17B10 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.